Fig. 2

Adjusted mean change from baseline in bone erosion depth of the 2–3 metacarpal heads at 6 months. Assessed by HR-pQCT (primary endpoint, full analysis set). Error bars represent 95% CI. Numerators reflect the number of patients with available data on erosion parameters, and denominators, the number of bone erosions. P value is the statistical difference in the csDMARDs plus denosumab vs csDMARD therapy alone group. For adjusted mean as the primary endpoint, a linear mixed effect model analysis was performed using treatment group, sex, anti-CCP antibody (positive vs negative), and baseline DAS28-ESR as fixed effects; patients as random effects; and baseline values as covariates. CCP, cyclic citrullinated peptide; CI, confidence interval; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; DAS28-ESR, Disease Activity Score in 28 joints for rheumatoid arthritis with erythrocyte sedimentation rate as fixed effects; HR-pQCT, high-resolution peripheral quantitative computed tomography